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Induction of labour at 41 weeks versus expectant management 
until 42 weeks (INDEX): multicentre, randomised non-inferiority 
trial
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Joris AM van der Post,1 Ben Willem Mol,6 Esteriek de Miranda1
ABSTRACT
OBJECTIVE
To compare induction of labour at 41 weeks with 
expectant management until 42 weeks in low risk 
women.
DESIGN
Open label, randomised controlled non-inferiority 
trial.
SETTING
123 primary care midwifery practices and 45 hospitals 
(secondary care) in the Netherlands, 2012-16.
PARTICIPANTS
1801 low risk women with an uncomplicated singleton 
pregnancy: randomised to induction (n=900) or to 
expectant management until 42 weeks (n=901).
INTERVENTIONS
Induction at 41 weeks or expectant management until 
42 weeks with induction if necessary.
PRIMARY OUTCOME MEASURES
Primary outcome was a composite of perinatal mortality 
and neonatal morbidity (Apgar score <7 at five minutes, 
arterial pH <7.05, meconium aspiration syndrome, 
plexus brachialis injury, intracranial haemorrhage, and 
admission to a neonatal intensive care unit (NICU). 
Secondary outcomes included maternal outcomes and 
mode of delivery. The null hypothesis that expectant 
management is inferior to induction was tested with a 
non-inferiority margin of 2%.
RESULTS
Median gestational age at delivery was 41 weeks+0 
days (interquartile range 41 weeks+0 days-41 
weeks+1 day) for the induction group and 41 
weeks+2 days (41 weeks+0 days-41 weeks+5 days) 
for the expectant management group. The primary 
outcome was analysed for both the intention-to-
treat population and the per protocol population. In 
the induction group, 15/900 (1.7%) women had an 
adverse perinatal outcome versus 28/901 (3.1%) 
in the expectant management group (absolute risk 
difference −1.4%, 95% confidence interval −2.9% to 
0.0%, P=0.22 for non-inferiority). 11 (1.2%) infants 
in the induction group and 23 (2.6%) in the expectant 
management group had an Apgar score <7 at five 
minutes (relative risk (RR) 0.48, 95% CI 0.23 to 0.98). 
No infants in the induction group and three (0.3%) in 
the expectant management group had an Apgar score 
<4 at five minutes. One fetal death (0.1%) occurred in 
the induction group and two (0.2%) in the expectant 
management group. No neonatal deaths occurred. 
3 (0.3%) neonates in the induction group versus 8 
(0.9%) in the expectant management group were 
admitted to an NICU (RR 0.38, 95% CI 0.10 to 1.41). 
No significant difference was found in composite 
adverse maternal outcomes (induction n=122 
(13.6%) v expectant management n=102 (11.3%)) or 
in caesarean section rate (both groups n=97 (10.8%)).
CONCLUSIONS
This study could not show non-inferiority of expectant 
management compared with induction of labour in 
women with uncomplicated pregnancies at 41 weeks; 
instead a significant difference of 1.4% was found 
for risk of adverse perinatal outcomes in favour of 
induction, although the chances of a good perinatal 
outcome were high with both strategies and the 
incidence of perinatal mortality, Apgar score <4 at five 
minutes, and NICU admission low.
TRIAL REGISTRATION
Netherlands Trial Register NTR3431.
Introduction
Post-term pregnancy, defined as a pregnancy extended 
to or beyond 42 weeks, or 294 days or more, is associated 
with increased perinatal morbidity and mortality.1-10 
The World Health Organization and various guidelines 
throughout the world therefore recommend induction 
of labour after 42 weeks.10-15 Although the overall 
probability of favourable perinatal outcomes between 
40 and 42 weeks is good in high resource settings, the 
risk of adverse perinatal outcome increases gradually 
after 40 weeks.16-19
Several studies concluded that induction of labour 
from 41 weeks onwards improves perinatal outcomes, 
WHAT IS ALREADY KNOWN ON THIS TOPIC
A policy of labour induction at or beyond term compared with expectant 
management is associated with fewer perinatal deaths and fewer caesarean 
sections; but more operative vaginal births (Cochrane review)
Aggregated results of trials need to be interpreted with caution because of trials 
heterogeneity caused by different outcome measures, protocols, and time frames 
of comparison
Evidence is lacking for the recommendation to induce labour at 41 weeks instead 
of 42 weeks for the improvement of perinatal outcome
WHAT THIS STUDY ADDS
Induction of labour at 41 weeks resulted in less overall adverse perinatal 
outcome than a policy of expectant management until 42 weeks, although the 
absolute risk of severe adverse outcome (perinatal mortality, NICU admission, 
Apgar score <4 at five minutes) was low in both groups
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and this has been confirmed in a meta-analysis.16 17 19 20 
These results need to be interpreted with caution, 
however, because of heterogeneity between trials as 
a result of different outcome measures, protocols, 
and time frames of comparison because several trials 
compared induction beyond 41 weeks or starting 
induction at 42 weeks with a policy of expectant 
management far beyond 42 weeks.21
The obstetric management of women with a 
pregnancy exceeding 41 weeks varies considerably 
between and within countries. Although induction 
at 41 weeks has now become an accepted policy in 
many countries, in some others no consensus exists 
on the timing of induction in late term pregnancy. In 
Sweden and the Netherlands, for example, expectant 
management until 42 weeks is considered standard of 
care in women with an uncomplicated pregnancy.15 22 
In Norway, induction is started no later than 42 weeks, 
and in Denmark delivery takes place before 42 weeks. 
Guidelines from the Royal College of Obstetricians and 
Gynaecologists/National Institute for Health and Care 
Excellence recommend that women should be offered 
induction between 41 and 42 weeks.23
We compared two strategies: induction of labour at 
41 weeks (+0 days/+1 day) and expectant management 
until 42 weeks (+0 days) with subsequent induction if 
necessary. We anticipated that a policy of expectant 
management at 42 weeks, being the simpler strategy, 
would be acceptable for a low risk population if it did 
not lead to a substantially higher proportion of women 
with adverse perinatal outcomes compared with 
induction at 41 weeks.
Methods
Study design
Because induction of labour at 41 weeks as well as 
expectant management until 42 weeks are practised 
in the Netherlands, our study was designed to 
investigate non-inferiority of expectant management. 
We conducted a multicentre, open label, randomised 
controlled non-inferiority trial to investigate the effect 
of INDuction of labour at 41 weeks with a policy of 
EXpectant management until 42 weeks (INDEX trial) on 
adverse perinatal outcomes. Women were recruited at 
123 primary care midwifery practices and 45 hospitals 
(secondary care) equally distributed across the 
Netherlands. Twenty six of these 45 hospitals actively 
recruited participants, and 19 supported the study by 
inducing labour in women who had been recruited in a 
primary care setting and were allocated to induction. In 
the Netherlands obstetric care is provided by primary 
care (midwives) for low risk women and secondary 
care (clinical midwives, residents, and obstetricians) 
for women with an increased risk of adverse maternal 
or perinatal outcome, or both. Low risk women in 
primary care can give birth at home or in an outpatient 
setting (birth centre or hospital), whereas women in 
secondary care give birth in hospital. For most low 
risk women, independent primary care midwives 
provide obstetric care. If risk factors are present 
during pregnancy, labour, or the postpartum period, 
women are referred to secondary care (obstetrician or 
gynaecologist). Secondary care may also be provided 
by clinical midwives or trainee obstetricians under the 
responsibility of an obstetrician.24-30
Our protocol has been published previously.31 The 
study was performed within the Dutch Consortium 
for Healthcare Evaluation and Research in Obstetrics 
and Gynaecology in cooperation with the Midwifery 
Research Network Netherlands.
Participants
Women were eligible for the study if they had a 
low risk, uncomplicated singleton pregnancy with 
the child in a stable cephalic position at a certain 
gestational age of 40 weeks+5 days to 41 weeks+0 days 
and no contraindications to expectant management 
until 42 weeks. Gestational age had to be determined 
by ultrasonography before a gestational age of 16 
weeks. Exclusion criteria for the study were age 
younger than 18 years, ruptured membranes or in 
labour, or both, non-reassuring fetal status (eg, no 
fetal movements, or abnormal fetal heart rate and/or 
expected intrauterine growth restriction), known fetal 
abnormalities (including abnormal karyotype) that 
could influence perinatal outcome, contraindications 
to induction (including previous caesarean section), 
or contraindications to expectant management (eg, 
pregnancy induced hypertension).
Randomisation and masking
Eligible women were informed about the study at the 40 
week antenatal check. At their next visit (40 weeks+5 
days to 41 weeks+0 days) the women were counselled 
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by the community midwife, secondary obstetric 
caregiver, or research-nurse or research-midwife of 
the participating centres collaborating in the Dutch 
Obstetric Research Consortium. After written informed 
consent had been obtained, the study participants 
underwent digital vaginal examination to determine 
the Bishop score which is used to assess the ripeness 
of the cervix before planning of induction of labour. It 
rates position, consistency, and dilation of the cervix 
and engagement of the fetal head (station) in a single 
score. Sweeping of the membranes was optional. 
Participants were randomly allocated by a web based 
program (ALEA) using randomly permuted block sizes 
of 4 and 2, stratified by centre to induction of labour at 
41 weeks+0 days-1 week or to expectant management 
with subsequent induction if necessary at 42 weeks+0 
days. Owing to the nature of the intervention it was not 
possible to blind the women or caregivers to treatment 
allocation.
Procedures
Women allocated to induction were scheduled for the 
procedure at 41 weeks+0 days-41 weeks+1 day. All 
women were primed or induced, or both according 
to local protocols. Women with a Bishop score of less 
than 6 received cervical priming with prostaglandin 
E1 (misoprostol, oral or vaginal), prostaglandin E2 
(dinoprostone), Foley catheter or double balloon 
catheter, or a combination of these until amniotomy 
could be performed. Amniotomy was followed by 
intravenous oxytocin if required.
Women in primary and secondary care who 
were allocated to expectant management awaited 
spontaneous onset of labour until 42 weeks+0 days 
in their initial care setting, with monitoring according 
to local protocol. Monitoring typically involved a 
combination of cardiotocography, and sonographic 
assessment of amniotic fluid in secondary care at 41-
42 weeks. Women in the expectant management group 
with ongoing pregnancies were scheduled for induction 
at 42 weeks+0 days in secondary care, following a 
similar induction protocol to the intervention group.
In both groups, labour was induced if the maternal 
or fetal condition was no longer reassuring—for 
example, reduced fetal movements, non-optimal 
cardiotocography findings, or oligohydramnios. Labour 
was also induced if prelabour rupture of membranes 
had occurred more than 24 hours previously or 
meconium stained amniotic fluid was present.
The caregivers systematically collected information 
on perinatal and maternal condition, as well as protocol 
deviations and the reasons for these. Every case report 
form was checked on completion and inconsistency. 
Trained staff entered data in an online digital case 
report form (Oracle Clinical, version 4.6.6.4.1). 
Anonymised source documents were collected at 
the midwifery practice or hospital to check adverse 
perinatal and maternal outcomes. Serious adverse 
events were reported on a case by case basis to an 
independent Data Safety and Monitoring Board and to 
the Dutch national internet portal for the submission, 
review, and disclosure of medical-scientific research 
with participants (www.toetsingonline.nl).
Outcomes
The primary outcome was a composite of perinatal 
mortality and neonatal morbidity. 
Perinatal mortality was defined as fetal death, 
intrapartum death, and neonatal death until 28 days. 
Neonatal morbidity was defined as having an Apgar 
score <7 at five minutes and/or an arterial umbilical 
cord pH <7.05 and/or meconium aspiration syndrome 
and/or plexus brachialis injury and/or intracranial 
haemorrhage and/or or being admitted to a neonatal 
intensive care unit (NICU). Though a neonate could 
suffer from more than one adverse event, it is counted 
as one composite adverse perinatal outcome (neonatal 
level). 
We defined meconium aspiration syndrome as 
respiratory distress after birth in the presence of 
meconium stained amniotic fluid. NICU admissions 
were reviewed to reveal final diagnosis and presence of 
congenital anomalies.
The cut-off for Apgar score <7 at five minutes was 
based on the committee opinion of the American College 
of Obstetricians and Gynecologists and American 
Academy of Pediatrics (ACOG/AAP), 2006. October 
2015, after trial registration and during inclusion 
for this study, the ACOG/AAP committee released an 
update, which stated that the inappropriate use of the 
Apgar score in outcome studies had led to an erroneous 
definition of asphyxia.32 Although it is incorrect to 
use Apgar score alone to diagnose birth asphyxia, an 
Apgar score <4 at five minutes “can be considered as a 
non-specific sign of illness.” Because of this mid-trial 
change of cut-off value, we also planned an additional 
analysis of the primary outcome including Apgar 
scores <4 instead of <7 at five minutes.
Secondary perinatal outcomes consisted of maternal 
outcomes: instrumental delivery (instrumental 
vaginal delivery, caesarean section), pain treatment 
(epidural, remifentanyl, pethidine), postpartum 
haemorrhage, and severe perineal injury (third or 
fourth degree perineal tear (obstetrical anal sphincter 
injuries (OASIS)). Other neonatal outcomes included 
admission to medium care, congenital abnormality, 
hypoglycaemia, neonatal infection or sepsis, and 
small for gestational age (<10th centile) or large 
for gestational age (>90th centile). We also added a 
composite of adverse maternal outcome and other 
delivery outcomes.
The composite adverse maternal outcome included 
postpartum haemorrhage (≥1000 mL), manual 
removal of the placenta, third or fourth degree 
perineal tear (obstetrical anal sphincter injuries), 
and admission to an intensive care unit (ICU). Other 
delivery outcomes concerned onset of labour, pain 
treatment during labour, use of tocolytics, maternal 
intrapartum infection, meconium stained amniotic 
fluid, gestational age at delivery, mode of delivery, 
episiotomy, total postpartum blood loss, and blood 
transfusion. Though a woman could experience more 
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than one adverse event, it is counted as one composite 
adverse maternal outcome.
For both the perinatal and the maternal composite 
outcomes, we also compared the individual 
components.
Statistical analysis
Before the start of the trial, we formed an expert 
panel, consisting of midwives, gynaecologists, and 
paediatricians, and methodologists to conceive the 
design, content, and execution of the trial. Using data 
on adverse perinatal outcomes in the Netherlands from 
the Perined registry (www.perined.nl/), we expected 
an incidence of 3% for the primary composite adverse 
perinatal outcome with both strategies. The panel made 
a reasoned choice about the acceptable difference in 
adverse perinatal outcome and feasibility of the trial. 
As a result, the non-inferiority margin (∆) was defined 
as a 2% risk difference in incidence of the composite 
outcome favouring induction to justify a possible 
change in management strategy of pregnancies 
reaching a gestational age of 41 weeks+0 days.
With a one sided α of 0.05, the study could achieve 
a power (β) of more than 0.80 if 900 women were 
recruited in each trial arm (1800 women in total). Non-
inferiority would be concluded if the lower limit of the 
95% confidence interval of the risk difference excluded 
a 2% higher proportion of women with an adverse 
perinatal outcome in the group allocated to expectant 
management. We established a Data Safety Monitoring 
Board to review the accumulating data of the trial. 
Interim analyses were conducted on safety after 517 
and 1088 women had been recruited.
The statistician who performed the analyses was 
blinded to the allocation of the participants and 
performed the analysis according to a predefined 
analysis plan. The analysis of the primary outcome 
was done for both the intention-to-treat groups and 
the per protocol groups. For the per protocol analysis, 
we selected all randomised women with start of 
cervical ripening or spontaneous onset of labour at 41 
weeks+0 days or more. Subsequently we defined the 
per protocol induction group as women allocated to 
induction who received induction before 41 weeks+2 
days or who had a spontaneous onset of labour before 
induction could be started (<41 weeks+2 days). The 
per protocol expectant management group included 
women allocated to expectant management with 
spontaneous onset of labour until 42 weeks+0 days, 
women with a medical reason for induction before 
42 weeks+0 days during expectant management, and 
women with induction at 42 weeks+0 days or more.
For all outcomes we estimated relative risks (RR) 
or median or mean differences, with 95% confidence 
intervals. As appropriate, we investigated significance 
using χ2 test, Fisher’s exact test, t test, or Mann-Whitney 
U test statistics. We plotted Kaplan-Meier curves for the 
time between randomisation and birth. The log-rank 
test statistic was used to evaluate the difference in time 
to birth. Birth centiles were determined using national 
reference data for the Netherlands on birthweight, 
ethnicity, parity, and gestational age by week and 
day. Analyses were performed using SAS software for 
Windows, version 9.4 (SAS Institute, Cary, NC).
Patient and public involvement
No patients were asked for input in the creation of 
this article. Patient representatives will be asked to 
join a multidisciplinary working group consisting of 
(representatives of) obstetric caregivers (primary and 
secondary care) and neonatologists to create a new 
nationwide guideline addressing the management of 
late term pregnancy. Patients will also be involved in 
writing patient information brochures and a patient 
decision aid on this topic.
Results
Between 14 May 2012 and 17 March 2016, 6088 eligible 
women were invited to participate in the INDEX trial, of 
whom 4273 declined owing to a maternal preference 
for induction of labour or expectant management, or 
refusal to let randomisation determine the management 
strategy. After randomisation but before analysis, 
one woman (induction group) withdrew her consent, 
and 13 women did not to meet the eligibility criteria 
(n=6 induction and n=7 expectant management). 
Of the remaining 1801 participants, 900 were 
randomly allocated to the induction group and 901 
to the expectant management group (fig 1). Baseline 
characteristics were comparable between the groups, 
except for nulliparity: induction 50.8% (457/900) and 
expectant management 56.7% (511/901). (table 1).
In the induction group, 28.9% (260/900) of the 
women had a spontaneous onset of labour before the 
planned induction, and 71.1% (640/900) underwent 
induction, of whom 59.7% (382/640) had cervical 
ripening (fig 2). In the induction group, 4.8% (43/900) 
of the women were not induced at 41 weeks+0 days–
41 weeks+1 days but at 41 weeks+2 days or later.
In the expectant management group, 73.7% 
(664/901) of the women had a spontaneous onset of 
labour and 26.3% (237/901) were induced (55.7% 
(132/237) underwent cervical ripening). In the expectant 
management group, 35.9% (85/237) underwent 
induction at 42 weeks for post-term pregnancy, and 
27.4% (65/237) underwent induction before 42 weeks 
due to medical reasons (eg, fetal condition in 15.6% 
(37/237), maternal condition in 9.7% (23/237)), 
whereas 36.7% (87/237) in the expectant management 
group underwent induction on request. The median 
gestational age at time of delivery was 287 days 
(interquartile range 287-288 days) corresponding with 
41 weeks+0 days (interquartile range 41 weeks+0 days-
41 weeks+1 day) for the induction group and 289 days 
(interquartile range 287-292 days), corresponding with 
41 weeks+2 days (41 weeks+0 days-41 weeks+5 days) 
in the expectant management group (table 2). In both 
groups three quarters of the women had a Bishop score 
<6 at study entry. Figure 3 shows the time to delivery for 
both groups.
In the per protocol induction group, 15.1% 
(92/611) of the women had spontaneous onset 
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of labour before the planned induction. Of these 
women, 11.1% (67/611) had a spontaneous onset 
of labour at 41 weeks+0 days and 4.1% (25/611) at 
41 weeks+1 day. In the per protocol induction group, 
84.9% (519/611) of the women were induced: 62.5% 
(382/611) at 41 weeks+0 days and 22.4% (137/611) 
at 41 weeks+1 day. In the per protocol expectant 
management group, 80.9% (524/647) of the women 
had a spontaneous onset of labour at 41 weeks+0 days 
or later and 19.0% (123/647) were induced: 5.4% 
(35/647) because of concerns about fetal condition 
at 41 weeks+0 days or later, 3.4% (22/647) because 
of maternal condition 41 weeks+0 days or later, 0.6% 
(4/647) because of rupture of the membranes more 
than 24 hours previously at 41 weeks+0 days or later, 
and 9.6% (62/647) because of post-term pregnancy 
(≥42 weeks+0 days).
Primary outcome
Table 3 presents the perinatal outcomes in the 
intention-to-treat analysis. Fifteen women in the 
induction group (1.7%) and 28 in the expectant 
management group (3.1%) had a composite adverse 
perinatal outcome (absolute risk difference −1.4%, 
95% CI −2.9% to 0.0%; number needed to treat (NNT) 
69, 95% CI 35 to 3059). The P value for non-inferiority 
was 0.22, indicating that we could not exclude that 
expectant management leads to 2% or more adverse 
perinatal outcomes compared with induction. All 
neonates in the expectant management group with 
a composite adverse perinatal outcome were born 
in secondary care. In these cases, women either had 
labour started in secondary care or were transferred 
during labour from primary to secondary care.
The per protocol analysis showed a 1.6% risk of an 
adverse perinatal outcome (10/611) in the induction 
group compared with 2.9% (19/647) in the expectant 
management group (risk difference −1.3%, 95% 
CI −3.0% to 0.4%, P=0.21 for non-inferiority; see 
supplementary appendix).
Additional analysis of the composite primary 
outcome including Apgar score <4 at five minutes 
instead of <7 resulted in 0.4% (4/900) adverse 
perinatal outcomes in the induction group and 
1.3% (12/901) in the expectant management group 
(absolute risk difference −0.9%, −1.9% to 0.2%; NNT 
113, 57 to 4624, P=0.02 for non-inferiority).
The additional per protocol analysis of the composite 
primary outcome including Apgar score <4 at five 
minutes showed a 0.5% risk (3/611) of an adverse 
perinatal outcome in the induction group versus 1.2% 
(8/647) in the expectant management group (risk 
difference −0.7%, −2.0% to 0.5%, P=0.02 for non-
inferiority; see supplementary appendix).
Lost to follow-up
0
Lost to follow-up
0
Analysed
Excluded from analysis
Per protocol expectant management
0
647
Allocated to intervention:
induction of labour at 41 weeks
Received allocated intervention
Did not receive allocated intervention:
  Withdrew informed consent (before
    intervention started)
  Not eligible:
     Too early/late for randomisation (40 weeks
      +0 days; 40 weeks+4 days; 41 weeks+2 days)
     Incorrect gestational age and pregnancy
      induced hypertension (38 weeks)
     Broken membranes
     Maternal disease
900
7
1
6
3
1
1
1
Assessed for eligibility
Randomised
Excluded
Refused intervention by randomisation
Preferred induction at 41 weeks
Preferred expectant management until 42 weeks
Other reasons (eg, planned home delivery)
722
616
2603
282
6088
1815
4273
907
Allocated to control:
policy of expectant management until 42 weeks
with subsequent induction as necessary
Received allocated intervention
Did not receive allocated intervention:
  Not eligible:
     Too early for randomisation (39 weeks+0 days;
       39 weeks+4 days)
     Non-stable cephalic position
     High blood pressure
     Non-reassuring fetal status
     Previous caesarean section
901
7
7
2
1
1
2
1
908
901
Analysed
Excluded from analysis
Per protocol immediate induction
0
611
900
Fig 1 | Flow of women through study
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Three perinatal deaths (stillbirths) occurred: one 
in the induction group and two in the expectant 
management group. There were no neonatal deaths. 
The stillbirth in the induction group was in a 30 year 
old multiparous woman who was randomised at 40 
weeks+5 days and scheduled for induction at 41 
weeks+1 day. She had reduced fetal movements at 
40 weeks+6 days, and fetal death was diagnosed at 
consultation. She delivered a neonate weighing 3595 
g (20th to 50th centiles). Investigations, including a 
postmortem examination, did not explain the stillbirth. 
In the expectant management group, stillbirth was 
diagnosed in a 36 year old nulliparous woman at 41 
weeks+3 days, when she was admitted to hospital in 
labour. She delivered a neonate weighing 2945 g (5th 
to 10th centiles). Investigations, including placental 
examination, did not explain the stillbirth, and the 
parents declined a postmortem examination. The 
second stillbirth in the expectant management group 
was diagnosed in a 32 year old multiparous woman 
at 41 weeks+4 days during a regular consultation in 
secondary care for impending post-term pregnancy. 
She delivered a neonate weighing 3715 g (20th to 50th 
centiles). No postmortem examination was performed, 
but the placenta showed signs of chorioamnionitis.
The main contributor to the composite adverse 
outcome was an Apgar score <7 at five minutes: 1.2% 
(11/900) of neonates in the induction group and 2.6% 
(23/901) in the expectant management group (RR 
0.48, 95% CI 0.23 to 0.98). Three of these neonates, 
all in the expectant management group, had an 
Apgar score <4 at five minutes. The first neonate was 
born at 41 weeks+6 days after spontaneous onset of 
labour and an operative vaginal delivery (vacuum), 
because of fetal distress and failure to progress in 
second stage. The diagnosis was meconium aspiration 
syndrome, and the neonate was admitted to the NICU 
(table 4). Sepsis after spontaneous onset of labour at 
40 weeks+6 days and rupture of membranes of more 
than 24 hours was diagnosed in the second neonate. 
The third neonate, weighing 4320 g, was born after 
cervical ripening that started at 41 weeks+6 days 
and failure to progress of second stage followed by a 
caesarean section at 42 weeks+2 days. The diagnosis 
in this neonate was airway obstruction caused by 
vernix caseosa. Both these neonates were admitted to 
a medium care unit for observation. All three neonates 
recovered without complications. Admission to an 
NICU was reported in 0.3% (3/899) of neonates in the 
induction group versus 0.9% (8/899) in the expectant 
management group (RR 0.38, 95% CI 0.10 to 1.41). Of 
the 11 children admitted to the NICU, six (three in each 
group) had a diagnosis of severe congenital disorder. 
Meconium aspiration syndrome was diagnosed twice, 
but only in the expectant management group, and 
both neonates recovered fully. No plexus brachialis 
lesions and no intracranial haemorrhage were 
diagnosed in the study population. In two admissions 
because of a (suspected) infection, one neonate had 
group B streptococcus and the other had a negative 
culture result. One neonate was admitted because of 
a pneumothorax.
Arterial pH measurements were not recorded 
systematically and therefore could not be included 
in the analysis. Imputing was not possible owing 
to many missing data (62.0% induction v 70.0% 
expectant management). However, when we analysed 
data including the available pH measurements, the 
composite adverse perinatal outcome was 27/900 
(3.0%) in the induction group versus 37/901 (4.1%) 
in the expectant management group (risk difference 
−1.11%, 95% CI −2.84% to 0.63%, P=0.16 for 
non-inferiority). For the per protocol analysis, the 
composite adverse perinatal outcome including the 
available pH measurement was 3.1% (19/611) in 
the induction group versus 4.0% (26/647) in the 
expectant management group (risk difference −0.91%, 
−2.98 to 0.01%, P=0.15 for non-inferiority).
When stratifying by parity, we observed 2.4% 
(11/457) nulliparous women with a composite adverse 
Table 1 | Baseline characteristics of participants by intervention group. Values are 
numbers (percentages) unless stated otherwise
Characteristics
Induction of labour 
(n=900)
Expectant management 
(n=901)
Mean (SD) maternal age (years): 30.6 (4.8) 30.2 (4.6)
 18-34 728 (80.9) 758 (84.2)
 35-39 148 (16.4) 132 (14.7)
 ≥40 24 (2.7) 11 (1.2)
Ethnicity:
 White 779 (86.6) 767 (85.1)
 Other 121 (13.4) 134 (14.9)
Body mass index at start of pregnancy:
 <18.5 26 (2.9) 19 (2.1)
 18.5-<25 532 (59.1) 523 (58.1)
 25-<30 230 (25.6) 229 (25.4)
 ≥30 89 (9.9) 117 (13.0)
 Missing 23 (2.6) 13 (1.4)
Highest level of education:
 Primary school 7 (0.8) 4 (0.4)
 Secondary school 37 (4.1) 15 (1.7)
 Lower/medium professional education 358 (39.8) 350 (38.8)
 Higher professional education/university 286 (31.8) 322 (35.7)
 Other/unknown 212 (23.4) 210 (23.3)
Social economic status:
 Low 219 (24.3) 251 (27.9)
 Medium 401 (44.6) 365 (40.5)
 High 225 (25.0) 233 (25.9)
 Unknown 55 (6.1) 52 (5.8)
Parity:
 Nulliparous 457 (50.8) 511 (56.7)
 Multiparous 443 (49.2) 390 (43.3)
Previous post-term pregnancy (≥294 days)* 51/443 (11.5) 34/390 (8.7)
Level of care at recruitment:
 Primary 851 (94.6) 850 (94.3)
 Secondary 49 (5.4) 51 (5.7)
Bishop score at study entry
Nulliparous women:
 ≥6 47/457 (10.3) 71/511 (13.9)
 <6 360/457 (78.8) 365/511 (71.4)
 Missing 50/457 (10.9) 75/511 (14.7)
Multiparous women:
 ≥6 71/443 (16.0) 46/390 (11.8)
 <6 310/443 (70.0) 294/390 (75.4)
 Missing 62/443 (14.0) 50/390 (12.8)
Membrane sweeping before randomisation 286/900 (31.8) 343/901 (38.1)
*Numerator: multiparous women.
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perinatal outcome in the induction group and 4.1% 
(21/511) in the expectant management group (RR 
0.59, 95% CI 0.29 to 1.20). In multiparous women the 
incidence of adverse perinatal outcome was lower in 
both groups compared with nulliparous women: 0.9% 
(4/443) in the induction group and 1.8% (7/390) in the 
expectant management group (RR 0.50, 95% CI 0.15 
to 1.71). In logistic regression analysis, no interaction 
was found between parity and induction or expectant 
management.
Secondary outcomes
Table 3 shows the secondary perinatal outcomes in the 
intention-to-treat groups. No difference was found in 
medium care admissions, 6.6% and 6.7% (induction 
59/899 v expectant management 60/899). Small for 
gestational age (<10th centile), according to Dutch 
birthweight centiles, was similar between the groups: 
6.8% (61/900) in the induction group versus 6.9% 
(62/901) in the expectant management group. Overall, 
9.6% (86/900) of infants in the induction group were large 
for gestation age (>90th centile) versus 11.0% (99/901) 
in the expectant management group. The incidence of 
congenital abnormalities was similar between groups: 
1.8% in the induction group (16/900) versus 2.1% in the 
expectant management group (19/901).
Table 2 summarises the characteristics of labour 
and mode of delivery. Oxytocin was given significantly 
more often in the induction group than in the expectant 
management group (59.2% (533/900) and 39.4% 
(355/901) (RR 1.50, 95% CI 1.36 to 1.66)). Meconium 
stained amniotic fluid occurred significantly less often 
in the induction group compared with expectant 
management group (16.3% (147/900) and 22.8% 
(205/901) (RR 0.72, 95% CI 0.59 to 0.87). Ninety 
seven women in each group (10.8%) had a caesarean 
section (RR 1.00, 95% CI 0.77 to 1.31), mainly for non-
progressive labour at the first stage of labour (table 2).
Table 5 shows the results of adverse maternal 
outcomes in the intention-to-treat groups. The 
composite adverse maternal outcome occurred in 
13.6% (122/900) of the women in the induction group 
versus 11.3% (102/901) in the expectant management 
group (RR 1.20, 95% CI 0.94 to 1.53). Postpartum 
haemorrhage ≥1000 mL was the main contributor to 
the composite adverse maternal outcome and occurred 
in 9.1% (82/900) of women in the induction group 
versus 8.0% (72/901) in the expectant management 
group (RR 1.14, 95% CI 0.84 to 1.54). Manual removal 
of the placenta occurred in 5.1% (41/803) in the 
induction group versus 4.1% (33/804) in the expectant 
management group (RR 1.24, 95% CI 0.79 to 1.95). 
Obstetrical anal sphincter injuries were diagnosed 
in 3.5% (28/803) of women in the induction group 
versus 3.9% (31/804) in the expectant management 
group (RR 0.90, 95% CI 0.55 to 1.49). Three mothers 
(0.3%) in the induction group and two (0.2%) in the 
expectant management group were admitted to an ICU 
post partum (RR 1.50, 95% CI 0.25 to 8.97), all after 
postpartum haemorrhage. Blood loss in these women 
was 3000 mL, 5100 mL, and 7000 mL in the induction 
group and 3390 mL and 5000 mL in the expectant 
management group. No maternal deaths occurred. 
During labour, 29.4% (265/900) of the women in 
the induction group received epidural anaesthesia 
compared with 25.6% (231/901) in the expectant 
management group (RR 1.15, 95% CI 0.99 to 1.33).
Discussion
This randomised controlled trial compared the effect 
of induction of labour at 41 weeks with expectant 
management until 42 weeks with subsequent induction 
if necessary on perinatal and maternal outcomes in 
women with an uncomplicated pregnancy. A policy of 
induction resulted in a median reduction in gestational 
age at delivery of two days. We found a 1.4% difference 
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in composite adverse perinatal outcome favouring 
induction, although the absolute risk of severe adverse 
perinatal outcome (perinatal mortality, Apgar score <4 
at five minutes, admission to a neonatal intensive care 
unit (NICU) without severe congenital anomalies) was 
low in both groups.
Most of our primary composite outcomes can be 
attributed solely to the component Apgar score <7 at 
five minutes 73.3% (11/15) in the induction group v 
64.3% (18/28) in the expectant management group), 
which means that these neonates did not have any 
other adverse outcome besides the Apgar score being 
<7 at five minutes. We performed a post hoc analysis 
of the composite outcome including Apgar scores <4 
instead of <7 at five minutes owing to the American 
College of Obsetricians and Gynecologists/American 
Academy of Pediatrics (ACOG/AAP) mid-trial change 
in recommended cut-off value for Apgar score at five 
minutes indicating a non-specific sign of illness. A 
considerable lower incidence of adverse perinatal 
outcome was found in both groups (0.4% induction 
and 1.3% expectant management), with an absolute 
risk difference of −0.9% (95% confidence interval 
−1.9% to 0.2%) favouring induction, showing non-
inferiority of expectant management with respect to the 
predefined margin of 2% (P=0.02 for non-inferiority).
Comparison with other studies
The incidence of perinatal death in our study was one 
after induction compared with two after expectant 
Table 2 | Delivery outcomes in intention-to-treat population. Values are numbers (percentages) unless stated otherwise
Outcomes Induction of labour (n=900) Expectant management (n=901) Relative risk (95% CI) P value
Median (interquartile range) gestational age delivery (days) 287 (287-288) 289 (287-292) −2.1 (−2.3 to −1.9)* <0.001†
Mean (SD) time from randomisation to delivery (days) 2.1 (1.6) 4.2 (3.0) −2.2 (−2.5 to −2.0)* <0.001†
Level of care at onset of labour:
 Primary 255 (28.3) 619 (68.7) NC -
 Secondary 645 (71.7) 282 (31.3) NC -
Onset of labour:
 Spontaneous (reference) 260 (28.9) 664 (73.7) 1.00 -
 Induction 640 (71.1) 237 (26.3) 2.70 (2.41 to 3.04) <0.001
 Mode of induction: n=640 n=237
  Cervical ripening (catheter/prostaglandins) 382 (59.7) 132 (55.7) 1.07 (0.94 to 1.22) 0.30
  Amniotomy without oxytocin 87 (13.6) 34 (14.8) 0.95 (0.66 to 1.37) 0.77
  Amniotomy with oxytocin 156 (24.4) 59 (24.9) 0.98 (0.76 to 1.27) 0.87
 Indication for induction:
  Randomisation 634 (99.1) 0 (0.0) NC - 
  Post-term pregnancy 0 (0.0) 85 (35.9) NC -
  Fetal condition 5 (0.8) 37 (15.6) NC -
  Maternal condition 0 (0.0) 23 (9.7) NC -
  Elective or maternal request 1 (0.2) 87 (36.7) NC -
  Membranes ruptured >24 h 0 (0.0) 4 (1.7) NC -
  Other 0 (0.0) 1 (0.4) NC -
Use of oxytocin 533 (59.2) 355 (39.4) 1.50 (1.36 to 1.66) <0.001
Use of tocolytics 28 (3.1) 16 (1.8) 1.75 (0.95 to 3.22) 0.07
Maternal intrapartum infection: n=900 n=901
 Fever during labour (≥38°C) 50 (5.6) 46 (5.1) 1.09 (0.74 to 1.61) 0.67
 Use of antibiotics 48 (5.3) 35 (3.9) 1.37 (0.90 to 2.10) 0.14
Meconium stained amniotic fluid 147 (16.3) 205 (22.8) 0.72 (0.59 to 0.87) 0.001
Level of care at time of birth:
 Primary 129 (14.3) 309 (34.3) NC -
 Secondary 771 (85.7) 592 (65.7) NC -
Mode of delivery:
 Spontaneous vaginal 710 (78.9) 696 (77.2) 1.02 (0.97 to 1.07) 0.40
 Operative vaginal 93 (10.3) 108 (12.0) 0.86 (0.66 to 1.12) 0.27
 (Secondary) caesarean section 97 (10.8) 97 (10.8) 1.00 (0.77 to 1.31) 0.99
Indication successful operative vaginal delivery: n=93 n=108
 Failure to progress at second stage 39 (41.9) 49 (45.4) 0.92 (0.67 to 1.27) 0.63
 Suspected fetal distress 43 (46.2) 37 (34.3) 1.35 (0.96 to 1.90) 0.08
 Suspected fetal distress and failure to progress 10 (10.8) 22 (20.4) 0.53 (0.26 to 1.06) 0.07
 Maternal complication or other 1 (1.1) 0 (0.0) NA -
Indication for secondary caesarean section: n=97 n=97
 Failure to progress at first stage 29 (29.9) 21 (21.6) 1.38 (0.85 to 2.25) 0.19
 Failure to progress at second stage 12 (12.4) 18 (18.6) 0.67 (0.34 to 1.31) 0.24
 Failed operative vaginal delivery 6 (6.2) 12 (12.4) 0.50 (0.20 to 1.28) 0.22‡
 Suspected fetal distress 24 (24.7) 21 (21.6) 1.14 (0.68 to 1.91) 0.61
 Suspected fetal distress and failure to progress at first stage 7 (7.2) 8 (8.3) 0.75 (0.17 to 3.26) 1.00‡
 Suspected fetal distress and failure to progress at second stage 4 (4.1) 3 (3.1) 1.00 (0.26 to 3.88) 1.00‡
 Maternal complication or other 15 (15.5) 14 (14.4) 0.93 (0.48 to 1.83) 0.84
NC=not calculable; NA=not applicable.
*Mean (95% confidence interval) difference between groups.
†Mann-Whitney U test.
‡Fisher’s exact test.
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management. The corresponding risk ratio for perinatal 
death (RR 0.50, 95% CI 0.05 to 5.51) is comparable 
with that of the four studies (n=998) starting induction 
at 41 weeks (n=501) versus expectant management 
with varying upper limits of gestational age (n=497) 
included in a Cochrane systematic review (RR 0.33, 
95% CI 0.03 to 3.17).19 21 33
Congenital anomaly accounted for a substantial part 
of the NICU admissions in our trial, although it was 
an exclusion criterion at study entry. It is unknown 
if the outcome for these children would have been 
better if they had been born earlier, although it is 
unlikely (table 4). For these reasons we also analysed 
the primary composite outcome using an Apgar score 
<4 at five minutes and NICU admission without severe 
congenital anomalies. With these adapted adverse 
outcomes (perinatal mortality, Apgar score <4 instead 
of <7 at five minutes, and NICU admission without 
severe congenital anomalies), the absolute risk on the 
composite adverse perinatal outcome was substantially 
lower in both groups, with a still significant difference 
in favour of induction (0.1% (1/897)) versus expectant 
management (1.0% (9/898)): absolute risk difference 
−0.9%, 95% CI −1.6% to 0.2%; P=0.01 for non-
inferiority; P=0.02 for Fisher’s exact test; and NNT of 
112 (95% CI 63 to 491)).
Since in our trial all women in the 41 week 
induction group received obstetrician led intrapartum 
secondary care whereas in the expectant management 
group until 42 weeks 68.7% of the women received 
midwifery led primary care at start of labour and 
34.3% at time of birth, it could be suggested that our 
study is prone to performance bias (different care) and 
measurement bias (different assessment of neonates). 
Several studies, however, showed that Apgar scoring 
does not differ significantly between midwives and 
obstetricians.34 35 36 Furthermore, in our trial all 
neonates in the expectant management group with 
an adverse outcome were born in secondary care—the 
women had started labour in secondary care or were 
referred from primary to secondary care during labour. 
Various studies have shown that it is safe for low risk 
women in the Netherlands to deliver in midwifery led 
care, and the level of care does not seem to influence 
delivery outcome for these women.24-28 Although this 
study could be considered as a comparison between 
obstetrician led care with labour induction and midwife 
led care with a policy of expectant management, 
we cannot adjudicate whether the difference in the 
composite adverse perinatal outcome is due to the level 
of care (performance bias) or to a possible difference 
in Apgar scoring (measurement bias). We do not, 
however, expect bias to be a major factor.
In our study, meconium aspiration syndrome occurred 
in two neonates in the expectant management group. 
In a randomised controlled trial with a comparable 
time frame, Gelisen et al reported meconium 
aspiration syndrome in 16/600 neonates of whom 
12/300 were in the expectant management group. 
We found a 10 and 20 times lower rate of meconium 
aspiration syndrome (0.0% and 0.2% versus 1.3 and 
4%) in the induction and expectant management 
groups compared with the study by Gelisen et al. Since 
these authors did not specify meconium aspiration 
syndrome, the difference in magnitude could be 
attributed to a difference in definition. Despite this, 
Gelisen et al found no difference in NICU admissions 
(4.3% induction v 5.0% expectant management), 
which is expected to be associated with meconium 
aspiration syndrome. We found a lower rate of NICU 
admissions compared with the Cochrane systematic 
review on induction of labour at more than 41 weeks: 
0.3% induction and 0.9% expectant management 
(INDEX trial) v 11% induction and 12% expectant 
management (systematic review). The systematic 
review lacked details on NICU admission, such as 
diagnosis, potential association with gestational age, 
or presence of congenital anomalies, which hampers a 
clear comparison.16 33
We did not find differences in caesarean section or 
operative vaginal delivery rates, which is consistent 
with other large studies on induction of labour.37 38 
In the only study that compared the same timeframes 
as our study, the risk ratio for caesarean section was 
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Fig 3 | Time to delivery
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comparable for both groups, although the absolute risk 
was twice as high compared with that of our study. This 
could be due to other inclusion criteria (Gelisen et al, 
Bishop score <5) or differences in policy during labour, 
as reflected by differences in national overall caesarean 
rates in Turkey (53% v 16% in the Netherlands).35  39 
The Cochrane systematic review concluded that 
induction at or beyond 41 weeks is associated with 
lower caesarean section rates. The largest contribution 
to this outcome was from a randomised controlled trial 
in which women in the control group were induced 
only with oxytocin according to study protocol, 
whereas prostaglandin use was allowed in women 
with low Bishop scores in the induction group.16 Two 
other systematic reviews including the same trial 
concluded that the difference in caesarean section 
Table 4 | Admission to neonatal intensive care unit (NICU) by intervention
Allocation NICU admission: diagnosis Congenital anomaly Gestational age at birth
Induction Long QT syndrome Yes 40 weeks+6 days
Induction Mild mitralis insufficiency, persistent ductus arteriosus Yes 41 weeks+0 days
Induction Interstitial lung disorder Yes 41 weeks+1 days
Expectant management Diaphragm herniation, atrial septal defect, ventricular septal defect Yes 40 weeks+6 days
Expectant management Muscular ventricular septal defect Yes 41 weeks+5 days
Expectant management Vocal cord paresis, dysmorphic features Yes 41 weeks+5 days
Expectant management Infection (suspected, but culture was sterile) No 41 weeks+2 days
Expectant management Infection, Group B Streptococcus positive No 41 weeks+3 days
Expectant management Pneumothorax No 41 weeks+4 days
Expectant management Meconium aspiration syndrome No 41 weeks+2 days
Expectant management Meconium aspiration syndrome No 41 weeks+6 days
Table 3 | Perinatal outcomes in intention-to-treat groups
Outcomes
Induction of labour 
(n=900)
Expectant management 
(n=901) Relative risk (95% CI) P value
Composite adverse perinatal outcome* 15 (1.7) 28 (3.1) 0.54 (0.29 to 1.00) 0.045†
 with 5 min Apgar score <4 instead of <7 4 (0.4) 12 (1.3) 0.33 (0.11 to 1.03) 0.06†
 including arterial pH <7.05 27 (3.0) 37 (4.1) 0.72 (0.44 to 1.20) 0.16†
Stillbirth 1 (0.1) 2 (0.2) 0.50 (0.05 to 5.51) 1.00†
Neonatal death post partum 0 (0.0) 0 (0.0) NA -
Apgar score 5 mins post partum‡:
 <7 11 (1.2) 23 (2.6) 0.48 (0.23 to 0.98) 0.038
 <4 0 (0.0) 3 (0.3) NA -
Neonate admitted to:
 NICU 3/899 (0.3) 8/899 (0.9) 0.38 (0.10 to 1.41) 0.23†
 Medium care 59 (6.6) 60 (6.7) 0.98 (0.69 to 1.39) 0.90
Meconium aspiration syndrome§ 0 (0.0) 2 (0.2) NA -
Plexus brachialis injury 0 (0.0) 0 (0.0) NA -
Intracranial haemorrhage¶ 0 (0.0) 0 (0.0) NA -
Umbilical cord pH (arterial):
 <7.05 16 (1.8) 12 (1.3) 1.06 (0.51 to 2.20) 0.88
 Missing 557 (62,0) 629 (70,0) NA -
Congenital abnormality 16 (1.8) 19 (2.1) 0.84 (0.44 to 1.63) 0.61
Hypoglycaemia** 3 (0.3) 6 (0.7) 0.50 (0.13 to 2.00) 0.51†
Neonatal infection/sepsis†† 37 (4.1) 37 (4.1) 1.00 (0.64 to 1.56) 1.00
Female 453 (50.3) 463 (51.4) 0.98 (0.89 to 1.07) 0.65
Mean (SD) birthweight (g) 3685 (417.4) 3741 (430.0) −56.6 (−95.8 to −17.4)‡‡ 0.005
Small for gestational age:
 <2.3rd centile 13 (1.4) 11 (1.2) 1.18 (0.53 to 2.62) 0.68
 <10th centilethcentile 61 (6.8) 62 (6.9) 0.99 (0.70 to 1.39) 0.93
Large for gestational age:
 >90th centile 86 (9.6) 99 (11.0) 0.87 (0.66 to 1.14) 0.32
 >97th centile 15 (1.7) 27 (3.0) 0.56 (0.30 to 1.04) 0.07
NA=not applicable; NICU=neonatal intensive care unit.
*Composite outcome defined as perinatal mortality (fetal death, intrapartum death, and neonatal death until 28 days) or perinatal morbidity (a 5 minute 
Apgar score <7, and/or meconium aspiration syndrome, and/or plexus brachialis injury, and/or intracranial haemorrhage, and/or NICU admission). In 
the induction group all live births with a composite adverse perinatal outcome (CAPO) had either a 5 minute Apgar score <7 or a NICU admission. In the 
expectant management group, live births with a CAPO: two neonates had meconium aspiration syndrome, 5 minute Apgar score <7, and NICU admission; 
three neonates were admitted to NICU and also had a 5 minute Apgar score <7; three neonates were admitted to NICU but had no 5 minute Apgar score 
<7; 18 neonates had a 5 minute Apgar score <7 but no NICU admission.
†Fisher’s exact test. 
‡Apgar score of live births.
§Defined as respiratory distress after birth in presence of meconium stained amniotic fluid.
¶Defined as clinical signs of intracranial haemorrhage.
**Defined as glucose concentration <1.9 mmol/L and need for intravenous glucose.
††Defined as clinical suspected findings or proved positive blood culture result.
‡‡Mean (95% confidence interval) difference between groups.
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rate is possibly due to the influence of this study with 
incomparable study arms.17 20 40 Population based 
cohort studies showed conflicting results on the effect 
of induction on caesarean section rates.41-43 In the 
recently published ARRIVE (A Randomized Trial of 
Induction Versus Expectant Management) trial, low 
risk nulliparous women were randomised in the 39th 
week of pregnancy to be induced at 39 weeks+0 days 
to 39 weeks+4 days or to expectant management until 
41 weeks. No statistically significant difference was 
found in perinatal outcome (RR 0.80, 95% CI 0.64 to 
1.00), although fewer caesarean sections took place in 
the induction group (18.6% v 22.2%; RR 0.84, 95% CI 
0.76 to 0.93). Our study comprised more white women 
(86% v 44%), with a higher median age (30 v 24 years) 
and a lower percentage of body mass index ≥30 (12% 
v 52%), whereas 46% of the participants in our study 
were multiparous women and ARRIVE included only 
nulliparous woman. Caesarean section rates in our 
nulliparous low risk women were comparable between 
the groups: 18.6% in the induction group and 18.0% 
in the expectant group. This could be due to the 
differences in gestational age, baseline characteristics, 
indication for induction of labour, or indication for a 
caesarean section (suspected fetal distress or failure to 
progress).44
Our trial had some notable results besides those 
for the main outcomes. Around 85% of participating 
women were of white ethnicity. The risk of perinatal 
mortality beyond term has been shown to be higher 
in women of South Asian, African, and Mediterranean 
origin compared with white women.45 In our study, 
we were not able to assess the effect of induction 
in women of non-white ethnicity owing to the low 
number of women of other ethnic origin. Also, we were 
unable to assess the effect of age on adverse perinatal 
outcome because of the low number of participating 
older mothers (>35 years).
As in other studies on pregnancies at or beyond 41 
weeks, most women in our study had an unfavourable 
cervix, with a Bishop score of <6 at randomisation. 
Although induction was planned one or two days 
after randomisation, 28.9% of the women in the 
induction group had a spontaneous onset of labour 
Table 5 | Adverse maternal outcomes in intention-to-treat population. Values are numbers (percentages) unless stated 
otherwise
Adverse outcomes
Induction of labour 
(n=900)
Expectant management 
(n=901)
Relative risk  
(95% CI) P value
Composite adverse maternal outcome* 122 (13.6) 102 (11.3) 1.20 (0.94 to 1.53) 0.15
Maternal death 0 (0.0) 0 (0.0) NA -
Postpartum blood loss:
  <1000 mL (reference) 818 (90.9) 829 (92.0) 1.00 -
 ≥1000 mL 82 (9.1) 72 (8.0) 1.14 (0.84 to 1.54) 0.40
  1000-1499 mL 34 (3.8) 35 (3.9) 0.97 (0.61 to 1.54) 0.91
  1500-1999 mL 21 (2.3) 14 (1.6) 1.50 (0.77 to 2.93) 0.23
  ≥2000 mL 27 (3.0) 23 (2.6) 1.18 (0.68 to 2.04) 0.56
Median (interquartile range) postpartum blood 
loss (mL) 300 (200-500) 300 (250-500) - 0.18†
Transfusion (packed cells or plasma) 23 (2.6) 17 (1.9) 1.35 (0.73 to 2.52) 0.34
Manual removal placenta 41/803 (5.1) 33/804 (4.1) 1.24 (0.79 to 1.95) 0.34
Perineal tear: n=803 n=804
 Episiotomy (without tear) 234 (29.3) 246 (30.6) 0.95 (0.82 to 1.11) 0.52
 Obstetrical anal sphincter injuries 28 (3.5) 31 (3.9) 0.90 (0.55 to 1.49) 0.69
 Third degree tear 15 (1.9) 19 (2.4) 0.79 (0.40 to 1.54) 0.49
 Fourth degree tear 8 (1.0) 7 (0.9) 1.14 (0.41 to 3.14) 0.80‡
 Episiotomy and third degree tear 4 (0.5) 2 (0.3) 2.00 (0.37 to 10.90) 0.45‡
 Episiotomy and fourth degree tear 1 (0.1) 3 (0.4) 0.33 (0.03 to 3.20) 0.62‡
Maternal admission (highest level of care):
 Intensive care 3 (0.3) 2 (0.2) 1.50 (0.25 to 8.97) 0.66‡
 Medium care 5 (0.6) 5 (0. 6) 1.00 (0.29 to 3.45) 1.00‡
 Ward 271 (30.1) 277 (30.7) 0.98 (0.85 to 1.13) 0.77
Indications for maternal admission:
 Thromboembolic complications 0 (0.0) 0 (0.0) NA -
 Hypertensive disorders§ 5 (0.6) 14 (1.6) 0.36 (0.13 to 0.99) 0.06‡
 Postpartum blood loss 49 (5.5) 52 (5.8) 1.06 (0.72 to 1.54) 0.78
 Post-caesarean section 97 (10.8) 97 (10.8) 1.00 (0.77 to 1.31) 0.99
Pain treatment during labour: 420 (46.7) 386 (42.8) 1.09 (0.98 to 1.20) 0.10
 Remifentanil 128 (14.2) 129 (14.3) 0.99 (0.79 to 1.25) 0.95
 Pethidine/promethazine/other opiates 60 (6.7) 51 (5.7) 1.18 (0.82 to 1.69) 0.38
 Epidural anaesthesia 265 (29.4) 231 (25.6) 1.15 (0.99 to 1.33) 0.07
 Other 1 (0.1) 5 (0.6) 0.20 (0.02 to 1.71) 0.22‡
NA=not applicable.
*Defined as postpartum haemorrhage ≥1000 mL, and/or manual removal of placenta, and/or third or fourth degree tears (obstetrical anal sphincter 
injuries), and/or intensive care admission, and/or maternal death. Denominator for perineal tear are vaginal deliveries only.
†Mann-Whitney U test
‡Fisher’s exact test.
§Including pre-eclampsia, and HELLP syndrome.
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before induction started, compared with 73.7% in 
the expectant management group. Despite women 
with suspected or established intrauterine growth 
restriction being ineligible for inclusion in the study, the 
birthweight for 7% of the children was less than the 10th 
Dutch centile (61/900 induction and 62/901 expectant 
management), confirming the difficulty in diagnosing 
growth restricted babies at term. In the induction group, 
2/61 infants had a birthweight less than the 10th 
centile and an adverse perinatal outcome: one neonate, 
weighing 3100 g (<10th centile), had an Apgar score 
of 6 at five minutes after operative vaginal delivery by 
forceps because of fetal distress. The other neonate, 
weighing 2595 g (<2.3rd centile), had an Apgar score of 
6 at five minutes after caesarean section because of fetal 
distress, with an umbilical cord pH of 6.87, possibly due 
to hypotension of the mother after epidural analgesia 
for pain relief or multiple entanglement of the umbilical 
cord. In the expectant management group, 3/62 infants 
weighed less than the 10th centile at birth and had an 
adverse perinatal outcome: one (birthweight 2945 g) 
was a stillbirth, one (2980 g) was admitted to the NICU 
because of a pneumothorax, and one (3040 g) had an 
Apgar score of 6 at five minutes that was attributed to 
pethidine use in the mother.
Strengths and limitations of this study
A major strength of our study is that it concerns a 
nationwide multicentre randomised controlled trial of 
a well defined obstetrical population at low risk; the 
largest trial to date to compare induction of labour 
at 41 weeks with expectant management until 42 
weeks.46 No cases were lost to follow-up.
In the Netherlands, expectant management until 42 
weeks is the standard of care in the low risk obstetrical 
population at 41-42 weeks according to the Dutch 
Obstetrical Indication List, although there is wide 
variation in practice because of women and caregiver 
preferences, which complicated inclusion.15 Not all 
eligible women were invited, and not all women who 
were asked participated, because of a preference for 
induction or expectant management. Despite this 
selective participation, our trial offers the best possible 
representation of pregnant women reaching 41 
weeks+0 days in the Netherlands.
We are aware of some potential limitations of our 
trial. We chose to use a composite adverse perinatal 
outcome instead of a single outcome like perinatal 
mortality. We considered any major adverse perinatal 
outcome in an otherwise uncomplicated pregnancy as 
undesirable. It is debatable if all the included adverse 
perinatal outcomes in our composite outcome measure 
are relevant to identify real severe adverse perinatal 
outcome with an effect on an infant’s short term or 
long term health status. However, if we included 
an Apgar score of <4 instead of <7 at five minutes, 
according to the ACOG/AAP criteria, and excluded 
severe congenital abnormalities, induction of labour 
resulted in a statistically significant risk reduction of 
0.9%, although with a substantially lower incidence of 
the composite adverse outcome in both groups.
We chose the non-inferiority design because we 
did not expect the Dutch standard policy of expectant 
management in our low risk obstetrical population 
to be inferior to a policy of induction of labour but 
acceptable or preferable if leading to comparable 
outcomes.47 It is good practice to use a per protocol 
analysis in non-inferiority trials, as an intention-to-
treat analysis carries a risk of falsely rejecting the null 
hypothesis of inferiority. Because we did not reject the 
null hypothesis and do not conclude non-inferiority, 
we presented the intention-to-treat analyses first, since 
such analyses are more common in reports of clinical 
trials. We also reported the per protocol outcome of the 
primary outcome (see supplementary appendix for the 
other per protocol analyses).
We did not stratify randomisation by parity, because 
we expected a balanced allocation in both groups owing 
to the large study population. However, it did result in 
an imbalance between groups: 50.8% of nulliparous 
women in the induction group compared with 56.7% 
in the expectant management group. After stratifying 
by parity in an additional analysis, we observed 
similar results. A higher incidence of the composite 
adverse perinatal outcome was seen in the nulliparity 
group in both the induction group (nulliparous 2.4% 
v multiparous 0.9%) and the expectant management 
group (nulliparous 4.1% v multiparous 1.8%), which 
is in concordance with other studies.48 Furthermore, 
we saw no interaction between parity and induction of 
labour or expectant management in logistic regression 
analysis.
The measurement of arterial pH is not possible in 
primary care, and pH measurement is no standard 
policy for uncomplicated birth in most hospitals in the 
Netherlands. Because of the high number of missing 
pH measurements (60-70%) and the impossibility to 
impute, we could not include umbilical artery pH in the 
composite outcome, which could have led to selection 
bias. Including the available data on umbilical arterial 
pH in the analyses, however, did not alter the results.
The results of our study can be interpreted in 
different ways, which might have implications 
for standard practice. If the composite outcome 
is interpreted straightforwardly, there is a small 
benefit of induction at 41 weeks that could justify 
standard induction at 41 weeks. It could be argued, 
however, that a change of policy to earlier induction, 
concerning roughly one fifth of all women with 
a singleton pregnancy, is too rigorous in light of 
the relatively low incidence of perinatal mortality, 
gestational age associated NICU admission, and 
Apgar score <4 at five minutes as indicator for 
encephalopathy. This could justify expectant 
management if women want to avoid induction. On 
both sides of the spectrum, caregivers are challenged 
to provide neutral, evidence based counselling of low 
risk women in late term pregnancy on the pros and 
cons of induction. In a recent report by Walsh et al, 
women felt they were not offered a real choice when 
it came to management of their prolonged pregnancy, 
and this is confirmed by other studies; induction of 
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labour is often presented as an inevitable next step to 
women, without information provided on alternative 
management strategies.49-51
Conclusions and policy implications
Our large trial compared induction of labour at 41 
weeks with expectant management until 42 weeks 
and subsequent induction if necessary. Substantial 
larger trials are needed to evaluate differences in 
rare outcomes, such as perinatal mortality and 
NICU admission. A systematic review or individual 
participant meta-analysis on the comparison between 
41 weeks and 42 weeks could then be performed 
including findings from those studies as well as 
those of our own study. Future research could also 
focus on long term adverse perinatal outcome of both 
strategies, although this requires long term follow-up 
of children.46 In addition, a more tailored approach 
will need identification of women who could maintain 
pregnancy until 42 weeks or are at increased risk of 
adverse perinatal outcomes (eg, relational model).
The incidence of late term pregnancy varies 
between countries because of different management 
strategies.52 Women need to be counselled on the 
desired policy in late term pregnancy. In this trial, 
induction of labour at 41 weeks resulted in less overall 
adverse perinatal outcome than a policy of expectant 
management until 42 weeks, although the absolute 
risk of severe adverse outcome (perinatal mortality, 
NICU admission, Apgar score <4 at five minutes) was 
low in both groups. As with every intervention in the 
natural birth process, the decision to induce labour 
must be made with caution, as the expected benefits 
should outweigh possible adverse effects for both 
mother and child.53 The results of our study should be 
used to inform women approaching a gestational age 
of 41 weeks, so they can weigh the respective outcomes 
and decide whether to be induced at 41 weeks or to 
continue pregnancy until 42 weeks.
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